Joshua Brown, Pharm.D., Ph.D., M.S.

Joshua Brown

Assistant Professor

Pharmaceutical Outcomes and Policy



PHONE: 352-294-8593

CV: Link to CV



  • Ph.D., Pharmaceutical Outcomes & Policy, University of Kentucky
  • Pharm.D., University of Arkansas for Medical Sciences
  • M.S. Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences
  • B.S., Biochemistry, University of Arkansas

Biographical Sketch

Joshua Brown, Pharm.D., Ph.D., M.S., joined the department of pharmaceutical outcomes and policy as an assistant professor in 2016. He received his Doctor of Pharmacy and Master of Science degrees at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, before pursuing a Ph.D. in pharmaceutical outcomes and policy at the University of Kentucky College of Pharmacy. During his doctoral training, Brown worked as the UK-Humana-Pfizer Research Fellow in a unique partnership between academic, managed care and pharmaceutical stakeholders working to assign value to Pfizer’s products in Humana’s population. In his doctoral dissertation, he studied the utilization of vena cava filters for prevention of pulmonary embolism, focusing on the high utilization and low quality of care surrounding these devices, as well as the implementation of interventions to increase that quality of care. Brown has received funding from the Hematology/Oncology Pharmacists Association to investigate treatment patterns and effectiveness in cancer-associated venous thromboembolism. He has also conducted studies investigating inappropriate prescribing in the elderly, treatments for stroke prevention in atrial fibrillation and the burden of substance abuse.


  • International Society for Pharmacoeconomics and Outcomes Research
  • International Society for Pharmacoepidemiology
  • International Society for Thrombosis and Haemostasis

Research Interests

  • Pharmacoepidemiology
  • Health outcomes
  • Drug policy
  • Quality of care in hematology, cardiology and oncology

Select Publications

Brown JD, Pauly NJ, Doshi PA, Talbert JC. Neonatal Abstinence Syndrome (NAS) rates increase despite efforts to combat the opioid abuse epidemic. JAMA Pediatrics. 2016. doi:10.1001/jamapediatrics.2016.2150.

Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve non-valvular atrial fibrillation. J Manag care Spec Pharm. 2016 Nov;22(11):1319-1329.

Brown JD and Talbert JC. Hospital variation and patient characteristics associated with vena cava filter utilization. Medical Care. 2016 (In press). DOI: 0.1097/MLR.0000000000000599

Brown JD, Shewale AR, Dherange P, Talbert JC. Comparison of oral anticoagulant utilization for atrial fibrillation in the elderly in the post-DOAC era: therapeutic substitution or increased treatment? Drugs & Aging. 2016. DOI: 10.1007/s40266-016-0369-y

Brown JD, Talbert JC. Explained variation in hospital utilization of vena cava filters in Kentucky. JAMA Surgery. 2016. DOI: 10.1001/jamasurg.2016.1004

Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive Validity of the Beers and Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. J Am Geriatr Soc. 2016;64(1):22-30. doi:10.1111/jgs.13884.

Pauly NJ, Talbert JC, Brown JD. Low-Cost Generic Program Use By Medicare Beneficiaries: Implications For Medication Exposure Misclassification In Administrative Claims Data. J Manag care Spec Pharm. 2016;22(6):741-751. DOI:10.18553/jmcp.2016.22.6.741

Shewale AR, Borse MS, Brown JD, Li C. Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers. Drug Alcohol Depend. 2015;154:132-138.